{"id":628188,"date":"2026-09-26T14:18:09","date_gmt":"2026-09-26T14:18:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/628188\/"},"modified":"2026-09-26T14:18:09","modified_gmt":"2026-09-26T14:18:09","slug":"rezvilutamide-in-high-volume-mhspc-emj","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/628188\/","title":{"rendered":"Rezvilutamide in High-Volume mHSPC &#8211; EMJ"},"content":{"rendered":"<p>REZVILUTAMIDE plus <a href=\"https:\/\/www.emjreviews.com\/urology\/news\/adt-intensification-may-not-improve-prostate-cancer-survival\/\" rel=\"nofollow noopener\" target=\"_blank\">androgen-deprivation therapy (ADT)<\/a> was associated with longer radiographic progression-free survival (rPFS), delayed castration resistance and improved prostate-specific antigen (PSA) responses compared with bicalutamide plus ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).\u00a0<\/p>\n<p>The multicentre retrospective cohort study included patients treated between 2021 and 2024. Propensity-score matching produced 50 patients in each treatment group. Calendar year was incorporated as a covariate in prespecified sensitivity analyses to address potential treatment-era bias.\u00a0<\/p>\n<p>Median rPFS was 25.9 months with rezvilutamide compared with 16.1 months with bicalutamide (hazard ratio [HR]: 0.64; 95% confidence interval [CI]: 0.41\u20130.98; p=0.038).\u00a0<\/p>\n<p>Rezvilutamide Extended Disease Control\u00a0<\/p>\n<p>Time to castration resistance was also longer with rezvilutamide at 18.6 versus 11.4 months (HR: 0.61; 95% CI: 0.39\u20130.94; p=0.026), while time to PSA progression was 20.1 versus 12.9 months (HR: 0.57; 95% CI: 0.36\u20130.91; p=0.018).\u00a0<\/p>\n<p>PSA responses also favoured rezvilutamide. A PSA reduction of at least 50% occurred in 84% of patients receiving rezvilutamide compared with 62% receiving bicalutamide (p=0.011), while PSA reductions of at least 90% occurred in 50% and 28%, respectively (p=0.022).\u00a0<\/p>\n<p>Overall survival did not differ significantly between groups (HR: 0.85; 95% CI: 0.50\u20131.43; p=0.54), and symptomatic skeletal events were also not significantly different (HR: 0.82; 95% CI: 0.44\u20131.54; p=0.53).\u00a0<\/p>\n<p>Safety Comparable Between Treatment Groups\u00a0<\/p>\n<p>Grade 3 or higher adverse events occurred in 26% of patients receiving rezvilutamide and 24% receiving bicalutamide. Prespecified central nervous system related events were reported in 8% and 14%, respectively, with events defined using standardised criteria and independently reviewed by a neurologist.\u00a0<\/p>\n<p>An exploratory analysis included patients with prior docetaxel exposure, who represented 24% of each treatment group and had been excluded from the CHART trial. rPFS numerically favoured rezvilutamide in this subgroup (HR: 0.68; 95% CI: 0.30\u20131.55), although the analysis was underpowered.\u00a0<\/p>\n<p>The researchers concluded that rezvilutamide plus ADT provided superior disease control to bicalutamide plus ADT in high-volume mHSPC. The retrospective design and modest sample size limit definitive conclusions, particularly for subgroups, while longer follow-up is needed to assess potential survival differences.\u00a0<\/p>\n<p>Reference\u00a0<\/p>\n<p>Lou Y e tal. Rezvilutamide versus bicalutamide with androgen-deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer: a multicenter retrospective cohort study. Sci Rep. 2026;DOI:10.1038\/s41598-026-69117-x.\u00a0<\/p>\n<p>Featured image: Pixel-Shot on Adobe Stock\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"REZVILUTAMIDE plus androgen-deprivation therapy (ADT) was associated with longer radiographic progression-free survival (rPFS), delayed castration resistance and improved&hellip;\n","protected":false},"author":2,"featured_media":628189,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[85,46,141],"class_list":["post-628188","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-il","tag-israel","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/628188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=628188"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/628188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/628189"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=628188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=628188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=628188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}